These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 30401502)

  • 21. Selective inhibition of the kinase DYRK1A by targeting its folding process.
    Kii I; Sumida Y; Goto T; Sonamoto R; Okuno Y; Yoshida S; Kato-Sumida T; Koike Y; Abe M; Nonaka Y; Ikura T; Ito N; Shibuya H; Hosoya T; Hagiwara M
    Nat Commun; 2016 Apr; 7():11391. PubMed ID: 27102360
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
    Coutadeur S; Benyamine H; Delalonde L; de Oliveira C; Leblond B; Foucourt A; Besson T; Casagrande AS; Taverne T; Girard A; Pando MP; Désiré L
    J Neurochem; 2015 May; 133(3):440-51. PubMed ID: 25556849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis, biological evaluation and molecular modeling studies of imidazo[1,2-a]pyridines derivatives as protein kinase inhibitors.
    Lawson M; Rodrigo J; Baratte B; Robert T; Delehouzé C; Lozach O; Ruchaud S; Bach S; Brion JD; Alami M; Hamze A
    Eur J Med Chem; 2016 Nov; 123():105-114. PubMed ID: 27474927
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Small Molecule Inhibitors of DYRK1A Identified by Computational and Experimental Approaches.
    Yoon HR; Balupuri A; Choi KE; Kang NS
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32957634
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A.
    Falke H; Chaikuad A; Becker A; Loaëc N; Lozach O; Abu Jhaisha S; Becker W; Jones PG; Preu L; Baumann K; Knapp S; Meijer L; Kunick C
    J Med Chem; 2015 Apr; 58(7):3131-43. PubMed ID: 25730262
    [TBL] [Abstract][Full Text] [Related]  

  • 26. QSAR analysis of pyrazolidine-3,5-diones derivatives as Dyrk1A inhibitors.
    Koo KA; Kim ND; Chon YS; Jung MS; Lee BJ; Kim JH; Song WJ
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2324-8. PubMed ID: 19282176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DYRK1A kinase inhibitors with emphasis on cancer.
    Ionescu A; Dufrasne F; Gelbcke M; Jabin I; Kiss R; Lamoral-Theys D
    Mini Rev Med Chem; 2012 Nov; 12(13):1315-29. PubMed ID: 23016545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generation of highly potent DYRK1A-dependent inducers of human β-Cell replication via Multi-Dimensional compound optimization.
    Allegretti PA; Horton TM; Abdolazimi Y; Moeller HP; Yeh B; Caffet M; Michel G; Smith M; Annes JP
    Bioorg Med Chem; 2020 Jan; 28(1):115193. PubMed ID: 31757680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and optimization of an original V-shaped collection of 4-7-disubstituted pyrido[3,2-d]pyrimidines as CDK5 and DYRK1A inhibitors.
    Dehbi O; Tikad A; Bourg S; Bonnet P; Lozach O; Meijer L; Aadil M; Akssira M; Guillaumet G; Routier S
    Eur J Med Chem; 2014 Jun; 80():352-63. PubMed ID: 24793883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Indole-3-Carbonitriles as DYRK1A Inhibitors by Fragment-Based Drug Design.
    Meine R; Becker W; Falke H; Preu L; Loaëc N; Meijer L; Kunick C
    Molecules; 2018 Jan; 23(2):. PubMed ID: 29364148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Developing DYRK inhibitors derived from the meridianins as a means of increasing levels of NFAT in the nucleus.
    Shaw SJ; Goff DA; Lin N; Singh R; Li W; McLaughlin J; Baltgalvis KA; Payan DG; Kinsella TM
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2617-2621. PubMed ID: 28408219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Probing the ATP-Binding Pocket of Protein Kinase DYRK1A with Benzothiazole Fragment Molecules.
    Rothweiler U; Stensen W; Brandsdal BO; Isaksson J; Leeson FA; Engh RA; Svendsen JS
    J Med Chem; 2016 Nov; 59(21):9814-9824. PubMed ID: 27736065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation, regulation, and inhibition of DYRK1A.
    Becker W; Sippl W
    FEBS J; 2011 Jan; 278(2):246-56. PubMed ID: 21126318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meridianin derivatives as potent Dyrk1A inhibitors and neuroprotective agents.
    Yadav RR; Sharma S; Joshi P; Wani A; Vishwakarma RA; Kumar A; Bharate SB
    Bioorg Med Chem Lett; 2015 Aug; 25(15):2948-52. PubMed ID: 26048785
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-Guided Discovery of Potent and Selective DYRK1A Inhibitors.
    Weber C; Sipos M; Paczal A; Balint B; Kun V; Foloppe N; Dokurno P; Massey AJ; Walmsley DL; Hubbard RE; Murray J; Benwell K; Edmonds T; Demarles D; Bruno A; Burbridge M; Cruzalegui F; Kotschy A
    J Med Chem; 2021 May; 64(10):6745-6764. PubMed ID: 33975430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multi-step virtual screening to develop selective DYRK1A inhibitors.
    Koyama T; Yamaotsu N; Nakagome I; Ozawa SI; Yoshida T; Hayakawa D; Hirono S
    J Mol Graph Model; 2017 Mar; 72():229-239. PubMed ID: 28129593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and antiproliferative activity of novel polynuclear heterocyclic compounds derived from 2,3-diaminophenazine.
    Mahran AM; Ragab SSh; Hashem AI; Ali MM; Nada AA
    Eur J Med Chem; 2015 Jan; 90():568-76. PubMed ID: 25497130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors.
    Henderson SH; Sorrell F; Bennett J; Fedorov O; Hanley MT; Godoi PH; Ruela de Sousa R; Robinson S; Ashall-Kelly A; Hopkins Navratilova I; Walter DS; Elkins JM; Ward SE
    J Med Chem; 2021 Aug; 64(15):11709-11728. PubMed ID: 34342227
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and Biological Validation of a Harmine-Based, Central Nervous System (CNS)-Avoidant, Selective, Human β-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor.
    Kumar K; Wang P; Wilson J; Zlatanic V; Berrouet C; Khamrui S; Secor C; Swartz EA; Lazarus M; Sanchez R; Stewart AF; Garcia-Ocana A; DeVita RJ
    J Med Chem; 2020 Mar; 63(6):2986-3003. PubMed ID: 32003560
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Dual Inhibitor of DYRK1A and GSK3β for β-Cell Proliferation: Aminopyrazine Derivative GNF4877.
    Liu YA; Jin Q; Ding Q; Hao X; Mo T; Yan S; Zou Y; Huang Z; Zhang X; Gao W; Wu TY; Li C; Bursalaya B; Di Donato M; Zhang YQ; Deaton L; Shen W; Taylor B; Kamireddy A; Harb G; Li J; Jia Y; Schumacher AM; Laffitte B; Glynne R; Pan S; McNamara P; Molteni V; Loren J
    ChemMedChem; 2020 Aug; 15(16):1562-1570. PubMed ID: 32613743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.